Phase 1 Open-label Dose Escalation and Expansion Study of ZEN003365 in Subjects With Relapsed or Refractory Lymphoproliferative Malignancies or Acute Myeloid Leukemia

Trial Profile

Phase 1 Open-label Dose Escalation and Expansion Study of ZEN003365 in Subjects With Relapsed or Refractory Lymphoproliferative Malignancies or Acute Myeloid Leukemia

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs ZEN 3365 (Primary)
  • Indications Acute myeloid leukaemia; Lymphoproliferative disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Zenith Epigenetics Corp
  • Most Recent Events

    • 12 Nov 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 02 Oct 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
    • 19 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top